Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs

Drug Metabolism and Disposition

Volumn 30, Issue 2, 2002, Pages 183-190

  Sadowitz, Peter D ^a   Hubbard, Bradley A ^a   Dabrowiak, James C ^c   Goodisman, Jerry ^c   Tacka, Kirk A ^c   Aktas, Mehmet K ^a   Cunningham, Mary J ^b   Dubowy, Ronald L ^a   Souid, Abdul Kader ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b Department of Gynecologic Oncology ^*  (United States)

^c SYRACUSE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; CELL DNA; CISPLATIN; MESNA; N ETHYLMALEIMIDE; PLATINUM; THIOL DERIVATIVE; THIOL REAGENT;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL; CONTROLLED STUDY; DRUG BINDING; DRUG DNA BINDING; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BINDING SITES; CISPLATIN; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KINETICS; MERCAPTOETHYLAMINES; MONOCYTES; SULFHYDRYL REAGENTS; TUMOR CELLS, CULTURED;

EID: 0036148607     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.2.183     Document Type: Article

References (38)

1. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum (II)
2. Kinetic analysis of the cis-diamminedichloroplatinum (II)-cysteine reaction: Implications to the extent of platinum-DNA binding
3. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)
4. Cellular responses to cisplatin. The roles of DNA-proteins and repair
5. Characterization of the reactions of platinum antitumor agents with biologic and non-biologic sulfur-containing nucleophiles
6. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese banister ovary cells
7. Mechanisms of resistance to cisplatin
8. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: Comparison with in vitro adduct formation
9. Anticancer activity of cisplatin and related compounds
10. High resistance to cisplatin in human ovarian cell lines is associated with marked increase of glutathione synthesis
11. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide
12. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance
13. Nephrotoxicity and carcinogenic risk of cisplatin (CDDP) prevented by sodium 2-mercaptoethanc-sulfonate (mesna): Experimental results
14. Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminediehloroplatinum (II) and cis-diammine(1, 1-cyclobutanedicarboxylato)platinum (II) differ only in the kinetics of their interaction with DNA
15. Pharmacokinetics of amifostine and its metabolites in patients
16. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient
17. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients
18. Binding of cis-dichlorodiammine platinum (II) to metallothionein in Ehrlich cells
19. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines
20. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulfate
21. A complete kinetic study of GG versus AG platination suggests that the doubly aquated derivatives of cisplatin are the actual DNA binding species
22. Cellular distribution and cellular reactivity of platinum(II) complexes
23. The determination of platinum in biological materials by electrochemical atomic absorption spectroscopy
24. Determination of the acid dissociation constants for WR-1065 by proton NMR spectroscopy
25. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells
26. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure - A novel use of graphite furnace spectrometry
27. Platinum-sulfur interactions involved in antitumor drugs, rescue agents and biomolecules
28. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer
29. a values
30. Transport of cisplatin and bis-acetato-amminedichlorocyclohexal-amine platinum (IV) (JM216) in human ovarian carcinoma cell lines: Identification of a plasma membrane protein associated with cisplatin resistance
31. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: Drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study
32. Blood thiols following amifostine and mesna infusions, a Pediatric Oncology Group study
33. Determination of the chemoprotective agent WR-2721 (amifostine, Ethyol) and metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography
34. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulfate and diethyldithio carbamate
35. WR-2721 as a modulator of cisplatin- and carboplatin induced side effects in comparison with other chemoprotective agents: A molecular approach
36. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms
37. Platinum binding to metallothionine. Analysis of circular dichroism spectra of complexes formed between metallothionein and platinum from cis- and trans-diamminedichloroplatinum
38. DNA-protein and DNA interstrand cross linking by cis- and trans-platinum (II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity